2025-05-13 08:00
Biovica, a leader in blood-based cancer monitoring, has entered a reference lab agreement with Tempus, a leader in AI and data-driven precision medicine. Tempus will offer Biovica’s blood-based treatment monitoring test, DiviTum TKa, as part of...
2025-03-26 08:00
Biovica, a leader in blood-based biomarker assays in oncology, today announces that an abstract with DiviTum TKa in a biomarker algorithm will be presented by Karolinska Institutet (KI) at the annual AACR meeting in Chicago on April 25-30, 2025, providing...
2025-03-13 08:00
Quarterly sales doubled, expanding market potential exponentially Significant events during the third quarter Significant events after the end of the period Webcast:When: 13/3 2025 kl. 15.00 CETWhere: registration via: Biovica Q3 Report FY 2024/2025Broadcast...
2025-03-12 08:00
Today, Biovica, a leader in blood-based cancer monitoring, announces a partnership with Outcomes4Me, the developer of the leading direct-to-patient empowerment platform that provides personalized, evidence-based navigation to people diagnosed with cancer...
2025-03-10 08:00
Biovica, active in blood-based cancer monitoring, has secured a new work order (WO) valued at SEK 2.5 million for TKa testing services within its Pharma Services business. This marks the third work order signed with this customer, bringing the total value...
2025-03-05 08:00
Biovica, active in cancer monitoring, has signed a collaboration agreement with Eurobio Scientific, a leading French group in in vitro specialty medical diagnostics and life sciences, for DiviTum® TKa in Austria, Benelux, France, Germany, Switzerland...
2025-02-06 13:00
Biovica today announces that board member Ulf Jungnelius has resigned from the board at his own request, with immediate effect. Personal reasons are behind the decision. "Due to my current situation, I am unable to fully participate in the board's...
2025-02-06 08:00
The Nomination Committee prior to the 2025 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December...
2025-01-13 08:00
Biovica, active in blood-based cancer monitoring, has signed an order with a total value of 2.3 MSEK for TKa testing services within its Pharma Services business. The work order is signed with a UK-based pharma/biotech company to be used in a phase I/II...
2024-12-12 08:00
Significant events during the second quarter Significant events after the end of the period Webcast:When: 12/12 2024 kl. 15.00 CETWhere: registration via: Biovica Q2 Earnings Call, Thu, Dec 12, 2024 at 3 PM CETBroadcast language: in English CEO’s...
>4,500
Numbers of patients in studies
28
Publications
22
Pharma Projects